- Home
- Solutions
- By Diseases
- Ocular Neoplastic Diseases
- Intraorbital Cavernous Hemangioma
Intraorbital cavernous hemangioma (ICH) is a benign vascular tumor of the orbit that is very common among orbital neoplasms. Protheragen, being at the forefront of research service provision, offers a complete set of services for the creation of diagnostics and therapies for the ICH.
The intraorbital cavernous hemangioma (ICH) is a benign vascular tumor that is primarily located in the orbit, which can cause proptosis, diplopia, and some degree of visual loss. In the most intricately woven tissues, even the least harmful tumors are capable of putting immense strain upon the host, and ICH is no different. This tumor is the most frequently diagnosed primary orbital tumor in adults, particularly between the ages of 40-50. The lesion is deeply encapsulated within a fibrous layer and is meshed with large spaces that are lined with endothelium, so its histology is quite unique. The slow flow of blood within these lesions make them distinct from other vascular defects because they allow for more precise diagnostic and therapeutic methods.
Fig.1 Ocular structural analysis of intraorbital cavernous hemangioma. (Ayoub E., et al., 2022)
Histopathological Analysis
The diagnosis of a lesion is made by biopsy and histopathological examination. ICH has large, dilated vascular channels which are partly surrounded by a fibrous stroma and are lined by a single layer of endothelial cells. The diagnosis can be confirmed by immunohistochemical staining with the endothelial markers CD31 and CD34.
Molecular Diagnostics
With ICH, the associated genic mutations can now be revealed due to the breakthroughs made in molecular diagnostics. Alongside this, PIK3CA gene mutations can also be uncovered by Next Generation Sequencing's (NGS) capabilities, which help understand the tumor's origins and available therapeutics options.
| Therapeutics | Target | Description | Research Stage |
| Sclerotherapy with Bleomycin | Vascular Lesions | Sclerotherapy using intralesional bleomycin injections has shown promise in treating low-flow vascular lesions, including ICH. This approach involves injecting bleomycin directly into the tumor under CT guidance to induce sclerosis and reduce tumor size. | Clinical Trials |
| Propranolol | Vascular Endothelium | Propranolol, a beta-blocker, has been repurposed for treating vascular anomalies due to its ability to reduce blood flow and induce the regression of vascular lesions. It is currently being explored for ICH management. | Preclinical |
| Sildenafil | Vascular Endothelium | Sildenafil, a phosphodiesterase-5 inhibitor, has demonstrated potential in managing vascular anomalies by promoting vascular regression. Its application in ICH is still in the early stages of investigation. | Preclinical |
Disclaimer: Protheragen focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Protheragen specializes in the development of intraorbital cavernous hemangioma therapeutics through performing molecular diagnostics, drug development, and preclinical studies. Our diverse team of specialists works directly with the clients to create ICH-based novel therapies that efficiently solve the specific problems of ICH.
Protheragen specializes in the development of customized animal models for intraorbital cavernous hemangioma research. Our services include the design and generation of genetically engineered models, xenograft models, and chemically induced models. We also offer comprehensive in vitro models, such as 3D cell cultures and organoids, to study tumor biology and drug response. If you are interested in our services, please feel free to contact us.
References
Copyright © Protheragen. All rights reserved.